



**U.S. FOOD & DRUG  
ADMINISTRATION**



**MITA**  
MEDICAL IMAGING  
& TECHNOLOGY ALLIANCE  
A DIVISION OF **ACEMA**

# Quantitative Brain Amyloid PET Imaging-Technical Considerations

Thursday, November 17, 2022

08:30 AM EST to 5:00 PM EST

Hybrid Workshop

## *Objectives*

*This workshop aims to evaluate the role of quantitative positron emission tomography (PET) measures of amyloid deposition in the brain.*

---

## Welcome and Introductions

8:30am - 8:45am Venkata Mattay, FDA; Munir Ghesani, SNMMI;  
Sue Bunning, MITA; Alessandra Rovescalli, NIA

## Session I: Quantitative Brain Amyloid PET Imaging: Background

**Moderator:** William Jagust, University of California, Berkeley

- 8:45am - 8:55am **Introductory Comments**
- 8:55am - 9:20am **Brain Amyloid PET: Overview of Clinical and Investigational Uses**
- Reisa Sperling, Massachusetts General Hospital
- 9:20am - 9:45am **Characteristics of Brain Amyloid Tracers: Impact on Quantification**
- Victor Villemagne, University of Pittsburgh
- 9:45am - 10:30am **Session I Panel**
- Gil Rabinovici, University of California, SF
  - Jonathan McConathy, SNMMI
  - Phillip Kuo, University of Arizona
- 10:30am – 10:45am **Break**



## **Session II: Products for Brain Amyloid Imaging**

**Moderators: Daniel Krainak and Venkata Mattay, FDA**

- 10:45am - 11:00am     **Regulatory Perspectives on Technical Characteristics of Drugs for Brain Amyloid PET**  
• Venkata Mattay, FDA
- 11:00am – 11:15am     **Regulatory Perspectives on Devices for Brain Amyloid PET Quantitation**  
• Daniel Krainak, FDA
- 11:15am - 11:35am     **Amyloid Quantitation Methodologies**  
• Susan Landau, University of California, Berkeley
- 11:35am - 12:15pm     **Session II Panel**  
• C. David Cooke, Syntermed  
• Johan Lilja, Hermes Medical  
• Satoshi Minoshima, University of Utah  
• Jon Piper, MIM Software Inc  
• Marcus Steward, Siemens Medical Solutions
- 12:15pm - 1:15pm     **Lunch**

## **Session III: Quantitative Brain Amyloid PET Imaging Methodology, Metrics, Analytical Validity**

**Moderator: Daniel Krainak, FDA**

- 1:15pm – 1:45pm     **Semi-Quantitative and Quantitative Metrics**  
• Julie Price, Harvard University
- 1:45pm – 2:15pm     **Variability in Quantitative Brain Amyloid PET Metrics**  
• Juan Domingo Gispert, Universitat Pompeu Fabra
- 2:15pm – 2:45pm     **Session III Panel**  
• Juan Domingo Gispert, Universitat Pompeu Fabra  
• Roger Gunn, Imperial College London  
• Julie Price, Harvard University  
• Victor Villemagne, University of Pittsburgh
- 2:45pm – 3:00pm     **Break**



**U.S. FOOD & DRUG  
ADMINISTRATION**



**MITA**  
MEDICAL IMAGING  
& TECHNOLOGY ALLIANCE  
A DIVISION OF **RSNA**

## **Session IV: Quantitative Imaging in Staging of Disease, Prognosis, and Monitoring Disease Progression: Implications for Diagnostic Imaging Drug Labeling.**

**Moderator: Sue-Jane Wang, FDA**

- 3:00pm – 3:20pm      **Evaluation of Qualitative and Quantitative Imaging: Implications for Diagnostic Imaging Drug Labeling**
- Sue-Jane Wang, FDA
- 3:20pm – 4:00pm      **Industry and Academic Perspectives on Brain Amyloid PET**
- Val Lowe, Mayo Clinic
  - Gill Farrar, GE Healthcare
  - Andrew Stephens, Life Molecular Imaging
  - Mark A. Mintun, Avid Radiopharmaceuticals and Eli Lilly and Company
- 4:00pm – 4:10pm      **Patient's Perspective – Patient Advocacy Group**
- Maria C. Carrillo, Alzheimer's Association
- 4:10pm – 4:55pm      **Session IV Panel**
- Tammie Benzinger, Washington University
  - Gregory Klein, Roche
  - Jonathan McConathy, SNMMI
  - Mark Mintun, Avid Radiopharmaceuticals and Eli Lilly and Company
  - Stephen Salloway, Brown University
  - Reisa Sperling, Massachusetts General Hospital
- 4:55pm – 5:00pm      **Closing Remarks, Adjournment**
- Louis Marzella, FDA**